| Company Address 1256 Briarcliff Road NE Emtech Bio Suite 500 Atlanta, GA 30306 |
PSD Comments We believe that a ton of opportunities exist right now in technology, particularly within the NASDAQ 100 Comp. The NASDAQ is now more than 75% below it's high found in 2000. Bio-tech, however as a whole, is only down about 60% from it's high found at the same time almost nine years ago. This points to strength in this individual sector, and we have tried to identified several Micro Cap companies that we believe present unique opportunities. GOVX comes with a bit more risk than some of our other Bio-tech picks, but we have seen some bulking up in their balance sheet during the last year to a positive shareholder equity level. Much of the risk comes from a relatively large amount of shares outstanding, however, the stock has seen very steady volume for some time. The stock seems to have a potential floor in the dime range. Anything more than a short term trade in this stock would be advised only with great care. GeoVax Labs Inc.’s phase 2a human HIV vaccine trials are set for sites across North and South America, the Atlanta biotechnology company said recently. The trials are conducted in collaboration with The National Institutes of Health and the HIV Vaccine Trials Network. The trial will involve 150 vaccinees and 75 placebo participants. The vaccine regimen employs a two-component "prime-boost strategy." Trial participants will first be administered a GeoVax HIV-1 DNA vaccine which "primes" the immune system followed by the second vaccine, GeoVax's HIV-1 Modified Vaccinia Virus boost. Both vaccines express the three major proteins of the AIDS virus. These proteins mimic more than 50 percent of the components of the AIDS virus (HIV-1) but cannot cause AIDS. GeoVax AIDS vaccines are designed to prevent HIV-1 which causes AIDS. |
Business description GeoVax Labs, Inc., a clinical stage biotechnology company, engages in the research and development of human vaccines for diseases caused by human immunodeficiency virus (HIV) and other infectious agents. Its vaccine candidates completed preclinical efficacy testing in non-human primates and a Phase I clinical study in humans. The company was founded in 2001 and is based in Atlanta, Georgia. Their goals include: developing AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting phase I/II and III human trials for vaccine safety and effectiveness and obtaining regulatory approval of these vaccines in the USA and specified international markets. |
| Market Cap: 88.68M Shares Outstanding: 745.20M Float: 604.76M % Held by Insiders: 50.21% |
| GOVX (OTC BB) Year Founded 2001 # of Employees 10 Employees Website www.geovax.com |
| 3 Months Avg. Price: 0.140 1 Month Avg. Price: 0.130 10 Days Avg. Price: 0.120 5 Days Avg. Price: 0.120 |
| Months Avg. Volume: 356.70K 1 Month Avg. Volume: 323.15K 10 Days Avg. Volume: 347.83K 5 Days Avg. Volume: 297.95K |
as of 12/8/08
as of 12/8/08
as of 12/8/08